RxDoctor Payments Data

Jeffery Alford, MD

Family Medicine · Sugarland, TXNPI 1932175999

Payments from drug & device makers

$13,967in general payments, 2019–2025

Across 605 payments — averaging $23.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Adamis Pharmaceuticals Corporation$3K
  • Amgen$989
  • Lilly USA, LLC$964
  • AbbVie$810
  • AstraZeneca$798
  • Novo Nordisk$785
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$10,42799%
  • Education$651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Adamis Pharmaceuticals Corporation6$3,475
Amgen65$989
Lilly USA, LLC52$964
AbbVie(2 entities)55$810
AstraZeneca46$798
Novo Nordisk40$785
Boehringer Ingelheim37$765
GSK41$645
Amarin Pharma, Inc.25$448
Pfizer26$432
Bayer21$395
Merck26$372
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC17$280
Antares Pharma, Inc.11$208
Takeda Pharmaceuticals U.S.A., Inc.10$203
Nobel Biocare USA5$147
Novartis8$146
Kowa Pharmaceuticals America, Inc.10$138
Medtronic1$126
Ironshore Pharmaceuticals Inc.5$123
Sanofi-aventis U.S. LLC7$122
Eisai Inc.6$117
Exact Sciences6$111
Sumitomo Pharma America, Inc.6$108
Esperion Therapeutics, Inc.5$84
Sanofi Pasteur Inc.4$78
Astellas Pharma US Inc3$76
Johnson & Johnson5$74
Idorsia Pharmaceuticals US Inc4$64
Shield Therapeutics Inc3$62
Redhill Biopharma Inc.3$60
Bausch Health US, LLC3$55
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$55
Biohaven Pharmaceutical Holding Company Ltd.3$51
Genentech USA, Inc.3$45
Renalytix AI, Inc.2$42
Otsuka America Pharmaceutical, Inc.2$36
Abbott2$36
Tolmar, Inc.2$35
Dexcom, Inc.2$35
Biohaven Pharmaceuticals, Inc.2$30
Alvogen Inc1$29
Azurity Pharmaceuticals, Inc.2$29
Corium, LLC2$27
Amneal Pharmaceuticals LLC2$25
Hologic Sales And Service, LLC1$24
Supernus Pharmaceuticals, Inc.1$23
Mannkind Corporation1$22
Axsome Therapeutics, Inc.1$19
Almatica Pharma LLC1$18
Procept Biorobotics Corporation1$16
Althera Pharmaceuticals LLC1$16
Scilex Pharmaceuticals Inc.1$14
Tolmar Pharmaceuticals, Inc.1$14
Therapeuticsmd, Inc.1$13
Neos Therapeutics, LP1$13
Bard Peripheral Vascular, Inc.1$13
IBSA Pharma Inc.1$12
Adlon Therapeutics L.p.1$11
Dynavax Technologies Corporation1$3

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,967 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$334,599
Medicare patients
422
Services billed
6,699

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin182$187,678
OzempicSemaglutide99$123,725
MounjaroTirzepatide61$67,974
FarxigaDapagliflozin Propanediol66$56,323
EliquisApixaban44$53,447
XareltoRivaroxaban42$34,694
Repatha SureclickEvolocumab33$34,065
KerendiaFinerenone40$32,621
RybelsusSemaglutide25$30,561
LinzessLinaclotide13$15,863
MyrbetriqMirabegron12$15,456
JanuviaSitagliptin Phosphate13$14,038
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$13,626
Lantus SolostarInsulin Glargine,hum.Rec.Anlog87$12,799
Ezetimibe421$10,834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$765$187,678182 claims
Novo NordiskOzempic, Rybelsus$785$154,286124 claims
Lilly USA, LLCMounjaro$964$67,97461 claims
AstraZenecaFarxiga$798$56,32366 claims
PfizerEliquis$432$53,44744 claims
Johnson & JohnsonXarelto$74$34,69442 claims
BayerKerendia$395$32,62140 claims
GSKTrelegy Ellipta, Shingrix, Arexvy$645$23,47960 claims
AbbVieLinzess, Synthroid$810$18,67758 claims
Astellas Pharma US IncMyrbetriq$76$15,45612 claims
MerckJanuvia$372$14,03813 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$203$8,10811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Sugarland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →